In accordance with the NMPA approval, Gyre intends to pursue an adaptive Phase 2/3 clinical trial design, combining dose exploration with efficacy confirmation, to efficiently evaluate pirfenidone's ...

Announcing a new article publication for BIO Integration journal. Pulmonary fibrosis (PF) is a progressive interstitial lung disease characterized by excessive extracellular matrix deposition and ...

Gyre Therapeutics (GYRE) announced that the National Medical Products Administration, NMPA, of the People’s Republic of China, PRC, has ...

For treating pulmonary fibrosis, presently the pharmacological arsenal involves only two drugs, pirfenidone and nintedanib, ...

Keep this leaflet with the medicine. You may need to read it again. Esbriet contains the active ingredient pirfenidone. Esbriet is used to treat Idiopathic Pulmonary Fibrosis (IPF). IPF is a ...

The trial will evaluate pirfenidone capsules for the treatment of radiation-induced lung injury (RILI), with or without immune-related pneumonitis (CIP). This regulatory milestone marks the ...